Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- M. Hallek, K. Fischer, S. Stilgenbauer
- Medicine, BiologyThe Lancet
- 2 October 2010
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection…
- S. Schnittger, C. Schoch, W. Hiddemann
- Medicine, BiologyBlood
- 1 July 2002
Besides the importance of FLT3-LM for biologic and clinical characterization of AML, its value as a marker for disease monitoring based on 120 follow-up samples of 34 patients is shown.
A novel hierarchical prognostic model of AML solely based on molecular mutations.
- V. Grossmann, S. Schnittger, C. Haferlach
- BiologyBlood
- 11 October 2012
A prognostic model for the entire AML cohort solely based on molecular markers is developed, providing a more powerful model for prognostication than cytogenetics.
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
- K. Fischer, P. Cramer, C. Wendtner
- MedicineJournal of Clinical Oncology
- 6 August 2012
Chemoimmunotherapy with BR is effective and safe in patients with previously untreated CLL, and 90.5% of patients were alive.
Sequential gene disruption in Candida albicans by FLP‐mediated site‐specific recombination
A new method is devised that is based on the repeated use of the URA3 marker for selection of transformants and its subsequent deletion by FLP‐mediated, site‐specific recombination, which eliminates the need for a negative selection scheme for marker deletion and minimizes the risk of mitotic recombination in sequential disruption experiments.
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
- K. Fischer, P. Cramer, C. Wendtner
- Medicine, BiologyJournal of Clinical Oncology
- 10 September 2011
Chemoimmunotherapy with BR is effective and safe in patients with relapsed CLL and has notable activity in fludarabine-refractory disease, and promising results encouraged us to initiate a further phase II trial evaluating the BR regimen.
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged…
- T. Büchner, W. Berdel, W. Hiddemann
- MedicineJournal of Clinical Oncology
- 1 June 2006
The regimen of one course with standard-dose cytarabine and one course for induction, and prolonged maintenance for postremission chemotherapy in patients with AML is not improved by additional escalation in cytotoxic treatment.
Comparative and functional genomics provide insights into the pathogenicity of dermatophytic fungi
- A. Burmester, E. Shelest, A. Brakhage
- BiologyGenome Biology
- 19 January 2011
The first genome sequences of two closely phylogenetically related dermatophytes, Arthroderma benhamiae and Trichophyton verrucosum, both of which induce highly inflammatory infections in humans, are reported, enlighten the genetic basis of fundamental and putatively virulence-related traits of dermatophyts, advancing future research on these medically important pathogens.
Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients
- C. Schoch, T. Haferlach, W. Hiddemann
- MedicineBritish Journal of Haematology
- 1 January 2001
In conclusion, complex chromosome aberrations in de novo AML predicted a dismal outcome, even when patients were treated with intensive chemotherapy, and patients under the age of 60’years with complex aberrant karyotypes may benefit from HAM treatment during induction.
Evaluation of ZAP‐70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process
- R. Letestu, A. Rawstron, F. Ajchenbaum‐Cymbalista
- BiologyCytometry. Part B, Clinical cytometry
- 15 July 2006
A technical consensus was reached on the methods for cell permeabilization and immunophenotyping procedures for ZAP‐70 detection and reporting, and further work is underway to harmonize the preparation and analysis procedures.
...
...